Study on Medications for Obesity and Weight-Related Diseases

Study 1206

We are looking for overweight individuals to participate in a drug trial.

This study examines a drug currently in development for obesity and weight-related diseases. The purpose of the study is to evaluate the drug’s efficacy, safety, and tolerability compared with a placebo.

Target group: overweight individuals, ages 18 and older

Criteria for participation:

• Stable dose of weight-loss medication over the past 3 months (e.g., semaglutide, liraglutide, tirzepatide)
• A BMI of at least 30^kg/m² or at least 27^kg/m² with at least one weight-related condition (e.g., type 2 diabetes, high blood pressure, cardiovascular disease)
• If you have type 2 diabetes, you must have been diagnosed at least 90 days ago and your treatment must be stable
• Stable weight over the past 3 months
• Previously tried to lose weight without success
• Not have type 1 diabetes
• No history of pancreatitis
• Be willing to use a double barrier method for heterosexual intercourse, i.e., condom/be sterile (men) AND have approved contraception/be sterile/postmenopausal (women)

The study will last approximately 74 weeks and includes a 2-week screening period, a 16-week dose-titration period, a treatment period of approximately 1 year, and a 4-week follow-up period. During the study, you will receive either the study drug or a placebo.

The study is free of charge, and travel expenses may be reimbursed.

More information and registration

Would you like to participate in the study?Please submit an expression of interest using the form below.

Do you have any questions or want to know more?Call 018-30 33 99 or emailinfo@ctc-ab.se.

The study has been approved by the Swedish Ethical Review Authority and the Swedish Medical Products Agency. Your participation is voluntary, and you may withdraw at any time. The information you provide will be processed in accordance with the General Data Protection Regulation (GDPR).

Sign up here